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Abbreviations 
 
ADB   antibodies to DNAseB 
APC   antigen presenting cells 
ASO   antibodies to streptolysin 
BCR   B cell receptor 
BDV   Borna disease virus 
CMMC  colon migrating motor complex 
CNS   central nervous system 
CRP   C-reactive protein 
CSF   cerebrospinal fluid 
HLA   human leukocyte antigen 
IFN   interferon gamma 
IGFBP3  insulin-like growth factor binding protein3 
IL-   interleukin 
MCH   melanin-concentrating hormone 
MHC   major histocompatibility complex  
MHCI and MHCII major histocompatibility complex class I and II 
NP   nucleoprotein 
NREM  non-rapid eye movement sleep 
RA   rheumatoid arthritis 
REM   rapid eye movement sleep 
ROI   radical oxygen intermediates 
SLE   systemic lupus erythematosis 
TCR   T cell receptor 
TNF    tumour necrosis factor alpha 
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mTNF   membrane form of TNF 
sTNF   soluble form of TNF 
TNFRI and TNFRII tumour necrosis factor receptor I and II 
Trib2   Tribbles homolog 2 
 3
 
Summary 
Human narcolepsy with cataplexy is a neurological disorder which develops due to a 
deficiency in hypocretin producing neurons in the hypothalamus. There is a strong association 
with human leukocyte antigen HLA-DR2 and DQB1*0602. The disease typically starts in 
adolescence. Recent developments in narcolepsy research support the hypothesis of 
narcolepsy being an immune-mediated disease. Narcolepsy is associated with polymorphisms 
of the genes encoding T cell receptor alpha chain, tumour necrosis factor alpha and tumour 
necrosis factor receptor II. Moreover the rate of streptococcal infection is increased at onset of 
narcolepsy. The hallmarks of anti-self reactions in the tissue - namely upregulation of major 
histocompatibility antigens and lymphocyte infiltrates - are missing in the hypothalamus. 
These findings are questionable because they were obtained by analyses performed many 
years after onset of disease. In some patients with narcolepsy autoantibodies to Tribbles 
homolog 2 which is expressed by hypocretin neurons have been detected recently. Immune-
mediated destruction of hypocretin producing neurons may be mediated by 
microglia/macrophages which become activated either by autoantigen specific CD4+ T cells 
or superantigen stimulated CD8+ T cells, or independent of T cells by activation of 
DQB1*0602 signalling. Activation of microglia and macrophages may lead to the release of 
neurotoxic molecules such as quinolinic acid, which has been shown to cause selective 
destruction of hypocretin neurons in the hypothalamus. 
 
Key Words: molecular mimicry, T cell receptor, sleep, cytokines 
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Introduction 
Narcolepsy with cataplexy - a sudden, short loss of muscle tone triggered by emotions – is a 
disabling chronic brain disorder characterised by excessive daytime sleepiness, sleep 
paralysis, hallucinations, and disturbed nocturnal sleep. Although the severity of daytime 
sleepiness is fluctuating, it is present most of the time. Daytime sleepiness ranges from mild 
sleepiness that is easily overcome to excessive overwhelming and irresistible daytime 
sleepiness. The latter may manifest itself by episodes of daytime sleep occurring without 
warning (“sleep attacks”) (Bassetti and Aldrich, 1996, Dement et al., 1976). The prevalence 
of narcolepsy with cataplexy falls between 25 and 50 per 100.000 people (Longstreth et al., 
2007). There seems to be a slight male predominance. Age at onset lies between 15 and 40 
years in most cases.  
Up to 95% of patients with narcolepsy and cataplexy have low cerebrospinal fluid (CSF) 
hypocretin-1 levels (Baumann and Bassetti, 2005, Bourgin et al., 2008, Nishino et al., 2000). 
Autoptic data suggest that this deficiency reflects a loss of hypothalamic neurons which 
produce hypocretin peptides (hypocretin-1 and hypocretin-2; also known as orexins A and B) 
(Thannickal et al., 2000), which in turn bind to hypocretin receptors (hypocretin receptors-1 
and hypocretin receptors-2). The hypocretin system in sleep, wakefulness and narcolepsy has 
been discussed in detail elsewhere (for review see (Sakurai, 2007)). In brief, two independent 
studies in 1999 showed that mutations in the hypocretin-2 receptor gene is responsible for 
canine narcolepsy-cataplexy and a gene deletion of hypocretin in mice leads to a phenotype 
strikingly similar to human narcolepsy (Chemelli et al., 1999, Lin et al., 1999). Hypocretin-1 
and hypocretin-2, which are derived from a common precursor peptide, the prepro-orexin, 
share significant homology in their C-terminal part. Hypocretin-1 binds to two G protein–
coupled receptors named hypocretin receptor-1 and hypocretin receptor-2. Whereas the latter 
is a non selective receptor for both peptides, hypocretin receptor-1 is selective for hypocretin-
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1. Both hypocretin-1 and -2 are exclusively produced in the lateral hypothalamic area; their 
respective receptors are expressed in the entire central nervous system (CNS). In regard to the 
narcolepsy-like phenotype in animals with non-functional hypocretin or hypocretin receptor 
genes it is remarkable that hypocretin-1 and hypocretin-2 increase wake time and decreased 
rapid eye movement (REM) and non-REM (NREM) sleep time. The inability to maintain 
wakefulness seems to depend critically upon hypocretin-2, while the profound dysregulation 
of REM sleep control emerges from loss of signalling through both hypocretin receptor-1 and 
hypocretin receptor-2-dependent pathways ((Willie et al., 2003); for review see (Ohno and 
Sakurai, 2008)).  
In humans, only one patient with an early onset of disease in childhood has been reported to 
have a mutation in the hypocretin gene (Peyron et al., 2000), The aetiology of the reduction in 
the number of neurons containing detectable pro-hypocretin mRNA or hypocretin-like 
immunoreactivity in the hypothalamus in narcolepsy remains unexplained. Low hypocretin 
concentrations in the CNS may point to a failure of the neurons to produce hypocretin. In the 
normal hypothalamus, 80% of the hypocretin-producing neurons also express prodynorphin 
and neuronal activity-regulated pentraxin. The number of neurons expressing these gene 
products is reduced in proportion to the loss of hypocretin neurons (Blouin et al., 2005, 
Crocker et al., 2005). The selectivity of the loss of hypocretin neurons in the hypothalamus is 
shown by the absence of reduction in the number of neurons expressing melanin-
concentrating hormone (MCH) (Thannickal et al., 2009). In this review we will focus on 
immunological mechanisms possibly involved in the pathophysiology of the disease. 
 
Why should narcolepsy have anything to do with immunology? It is the association with 
HLA-DR2 genes and a newly discovered T cell receptor alpha polymorphism 
Narcolepsy is genetically characterized by strong linkage to distinct human leukocyte antigen 
(HLA) alleles. A genetic association of narcolepsy with HLA-DR2 and HLA-DQ1 in the 
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major histocompatibility (MHC) region was described more than 20 years ago (Langdon et 
al., 1984). High resolution typing by DNA techniques has further characterized the DR2 and 
DQ1 serological specificities associated with narcolepsy. As reviewed recently, the 
association between HLA class II genes and narcolepsy was present in all ethnic groups and 
the most tightly linked HLA allele was DQB1*0602 (Tafti, 2009). Whereas this allele is 
present in only 12-38% of the general population, more than 85% of the patients with 
narcolepsy-cataplexy have the HLA DQB1*0602 allele, most often in combination with 
HLA-DR2 (DRB1*1501) (Mignot, 1998). Moreover, the DQB1*0602 allele alone, 
particularly when homozygous, was the major narcolepsy susceptibility allele in different 
ethnic groups including African Americans, Caucasian-Americans and Japanese (Mignot et 
al., 2001). Several alleles have been identified that appeared to be protective (DQB1*0601, 
DQB1*0501 and DQA1*01) (Mignot et al., 2001).  
 
Among genetic factors linked to autoimmune disease development, MHC class II (MHCII) 
genes on chromosome 6 account for the majority of cases of familial clustering in common 
autoimmune diseases, and have also been linked to sporadic forms. In systemic lupus 
erythematosus (SLE), the most consistent HLA associations are with the MHCII allotypes, 
HLA-DR3 and HLA-DR2. A preeminent role of the extended haplotype defined by HLA-
DRB1*1501 has also been highlighted in recent studies on multiple sclerosis (Fernando et al., 
2008). The mechanisms that account for MHCII associated anti-self immunity remain poorly 
defined. Tolerance to self antigens is achieved by deletion of T cell precursors that express T 
cell receptors (TCR) having high avidity for self antigen – MHC complexes expressed on 
dendritic cells and epithelial cells in the thymus. Peripheral immune tolerance mechanisms 
control mature T cells that bear a TCR of low avidity for self antigen – MHC complexes and 
that escape from the thymus to the periphery (Mueller, 2010). A commonly held view is that 
disease associated HLA allotypes promote a breach of peripheral self-tolerance because they 
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favour the presentation of specific self-peptides to autoreactive T cells. Alternatively, the 
disease associated HLA allotypes could bias the TCR repertoire generated during T cell 
development in the thymus towards the selection of potentially pathogenic autoreactive 
specificities. It has also been proposed that autoimmunity might be promoted by ectopic or 
inappropriately high levels of HLA expression in the diseased tissues. An intriguing 
observation has been provided by crystallographic studies using a soluble form of DQ0602 
complexed with a peptide from human hypocretin (amino acids 1-13) (Siebold et al., 2004). 
The hypocretin peptide is presented in the DQ0602 binding grove with peptide side chains 
anchored in the P4 and P9 pockets. These pockets differ significantly between the DQ0602 
narcolepsy susceptibility molecule and DQ0601, an allele that is protective. Since no anti-self 
immunity to hypocretin has so far been detected, the significance of these studies remains 
open.  
The hallmarks of T cell involvement in autoimmune diseases are the presence of T cells 
sensitized to self antigens, dysregulated effector CD4+ T cells, such as TH17 cells, low titres 
of regulatory T cells, and inflammation at the sites of autoimmune attack. The inflammatory 
reaction is typically characterized by a local accumulation of CD4+ T cells and 
proinflammatory macrophages with increased expression of MHCII and cytokines. None of 
these characteristic features of T cell autoimmunity have been documented in narcolepsy. 
However, in a highly interesting recent study on T cell receptor alpha (TCR-) or -beta (TCR-
) subtypes, 807 narcolepsy patients positive for HLA-DQB1*0602 and exhibiting hypocretin 
deficiency in the CSF, as well as 1074 controls were selected for a genome-wide association 
study. The data identified an association between narcolepsy and polymorphisms in the TCR 
locus. The TCR chain is part of the TCR of CD8+ T cells, which recognize antigens 
presented by HLA class I molecules, and CD4+ T cells, which recognize antigens presented 
by HLA class II molecules, including the DQ (alpha)  (beta) heterodimer denoted DQ 
0602, which is encoded by the DQB1*0602 and DQA1*0102 alleles. Somatic recombination 
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in the TCR and TCR loci in developing T cells leads to the generation of a diverse 
repertoire of distinct TCR  idiotype-bearing T cells. Since narcolepsy is almost exclusively 
associated with a single HLA allele - DQB1*0602 - the authors suggest that the TCR 
polymorphism could contribute to autoimmunity directed against hypocretin neurons by 
influencing the occurrence of variable-joining region VJ2 recombinations that can interact 
with DQ0602 (Hallmayer et al., 2009).  
Another interesting observation has recently been described in a series of experiments 
reported by Carla Shatz. Since the initial report of MHCI expression and activity regulation in 
neurons, it has been suggested that altered MHCI expression contributes to synaptic changes 
and learning defects (for review see (Shatz, 2009)). In a search for MHCI-binding receptors, 
TCR mRNA was detected in neurons. However, TCR - the second obligatory component 
of a functional TCR – was not detected in neurons. As a hypothesis, polymorphism of the 
TCR- genes may influence the interaction with MHCI and thereby neuroprotection in 
disease states (Boulanger and Shatz, 2004). Some support for this comes from experiments 
with mice which lack either 2-microglobulin – a cosubunit for MHCI – or the transporter 
associated with antigen processing 1 (TAP1) required for loading antigen peptides onto 
MHCI molecules. Sciatic nerve transsection in both types of mutant mice showed axotomized 
-motoneurons to have more extensive detachments of synapses than those in wildtype mice 
(Oliveira et al., 2004). More sensitive techniques to detect TCR and  gene expression and 
studies on TCR – MHCI interactions on neurons are required to come to conclusions on the 
significance of MHCI expression by neurons.  
 
The strong association of narcolepsy with HLA-DQB1*0602 has prompted interest in the 
hypothesis that narcolepsy is an autoimmune disease. However, several issues relevant to this 
model deserve emphasis. (1) From a clinical point of view, a specific autoimmune disease is 
often associated with various other autoimmune manifestations in the affected individual or in 
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the family of the patient. Classical autoimmune diseases, such as SLE, rheumatoid arthritis 
(RA) or myasthenia gravis have not been reported to be increased in narcoleptic patients or 
their families. In fact, other autoimmune diseases (e.g. SLE, multiple sclerosis and 
neuromyelitis optica with anti-aquaporin-4 antibodies) have been observed only very rarely in 
narcoleptic patients (Baba et al., 2009, Pablos et al., 1993, Younger et al., 1991). (2) Unlike 
the situation observed in other autoimmune diseases, including SLE, RA and Sjögren 
syndrome, associated autoantibodies such as antinuclear antibodies, antibodies to nDNA, SS-
A, Sm, histone and rheumatoid factor are not increased in narcolepsy (Rubin et al., 1988). It 
is of note that no data are provided about the duration of the disease at the time point when 
the sera were taken for the study. (3) Intrathecal synthesis of immunoglobulins and 
oligoclonal bands are only rarely seen in the CSF of narcoleptic patients. One study reported 
two out of 15 patients to have oligoclonal bands and one of these to have an increased IgG 
index in the CSF. These patients had narcoleptic symptoms for 7 and 33 years, respectively 
(Fredrikson et al., 1990). In another study four of 22 patients with narcolepsy showed 
oligoclonal bands in the CSF. The disease duration was 8, 10, 12 and 30 years respectively. 
Measurement of antibodies to various viruses showed three patients to be positive for the 
herpes simplex virus (two patients) or cytomegalovirus (Schuld et al., 2004). The assays used 
are not sensitive enough to detect the production of antibodies to CNS antigens. (4) There is 
so far no evidence for the presence of antibodies to hypocretin or hypocretin receptor in the 
disease and antibodies to Tribbles homolog 2 (Trib2) which is expressed by hypocretin 
producing neurons have been detected in only 14% of narcoleptic patients (see below). (5) 
Autopsy studies have not shown an accumulation of T or B lymphocytes in the CNS, an 
influx of monocytes from the blood or an activation of microglia in the tissue, at least not at 
late time points of the disease (Table 1). The limited availability of tissues at early time points 
of the disease has hampered the search for autoantibodies and the detection of oligoclonal 
bands in CSF. (6) Finally, systemic markers indicating inflammation, such as increased blood 
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sedimentation and elevated C-reactive protein cannot be demonstrated. Since intravenous 
immunoglobulins proved effective in the treatment of various autoimmune diseases, it is 
interesting to look at the response of this treatment in narcoleptic patients. Several single 
observations point to beneficial effects when immunoglobulins are administrated close to 
disease onset (Plazzi et al., 2008). However, persistent improvements of narcoleptic 
symptoms were not observed in four other patients as recently reported (Valko et al., 2008). 
Taken together, these clinical findings do not support a role for local or even systemic 
autoimmunity in narcolepsy. Several of the aforementioned issues will be discussed in more 
detail below. 
 
Are anti-neuronal antibodies involved? 
Loss of hypocretin neurotransmission may be due to impaired production and/or secretion of 
hypocretin by neurons, or result from the loss of neurons that produce hypocretin. Several 
studies have addressed the hypothesis that autoantibodies may lead to alterations in the 
hypocretin system. An increased IgG index or oligoclonal bands were detected infrequently in 
the CSF of patients with narcolepsy (see above). Thus intrathecal synthesis of autoantibodies 
by local plasma cells is not a uniform finding of the disease (Fredrikson et al., 1990, Schuld et 
al., 2004). Furthermore, recent studies have failed to detect specific antibodies against 
hypocretin or hypocretin receptors (Black et al., 2005, Tanaka et al., 2006). In these studies 
no data are provided in regard to the time point of disease onset and sampling of the sera. No 
antibodies to hypothalamic neurons became detectable in the sera of 46 narcoleptic patients, 
the duration of illness being 23.6 10.6 years (Overeem et al., 2006). Likewise, antibodies to 
hypothalamic neurons were documented in only one of 9 patients, and the antibody epitope 
was not characterized (Knudsen et al., 2007). Insulin-like growth factor binding protein 3 
(IGFBP3), which is expressed in hypocretin neurons and downregulated in narcolepsy, has 
recently been identified as a potential new autoimmune target. However, no anti-IGFBP3 
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antibodies were detected in human sera or the CSF of patients. IGFBP3 concentrations in the 
CSF were not decreased (Honda et al., 2009). A new IgG antibody from patients with 
narcolepsy has been described to interfere with smooth muscle contractions in mouse colon 
preparations (Jackson et al., 2008). The epitopes of the antibodies detected in the assay 
remain unclear. Hypocretin is apparently not expressed in the murine gut (Baumann et al., 
2008).  
 
In a most recent, elegant search for proteins, which are expressed exclusively by hypocretin 
producing neurons, the screening approach came up with Trib2. While further 
characterization showed that Trib2 is not only expressed by hypocretin neurons, but also by 
other neurons, the study nevertheless points to Trib2 being an autoantigen in patients with 
narcolepsy (Cvetkovic-Lopes et al.). Using the 28 C-terminal amino acids of Trib2 in an 
ELISA assay, 20 (14%) of 143 narcoleptic patients had antibody titers of more than 2 SD 
above the mean titer of healthy controls. Only 2 (5%) out of 42 healthy controls had such 
antibodies (> 2 SD). The anti-Trib2 antibody titers were detected more often in the first year 
of disease onset. Immunhistochemistry showed that antibodies recognize hypocretin neurons 
in the mouse hypothalamus. However, the staining pattern looks cytoplasmic, which raises the 
question if the autoantibody would reach its intracellular antigen - Trib2- in vivo. Future 
studies should aim at (1) developing the ELISA system further in order to find other 
intramolecular epitopes which harbour more dominant B cell epitopes than the C-terminal 
part of the Trib2 protein, (2) testing for T cell responsiveness to Trip2, and (3) investigating if 
mice immunized with Trip2 or injected with anti-Trip2 antibodies will develop a narcolepsy-
like disease. Of note, 3 of 5 patients with uveitis have been identified to have anti-Trib2 
antibodies (Zhang et al., 2005). However, since the first description, the functional 
significance of the antibody detected in uveitis has not been further investigated.  
 
 12
Antibodies to intracellular antigens are common in old people and in a variety of infections 
and autoimmune diseases. However, these antibodies are not directly involved in causing 
disease. The same holds true for many of the anti-neuronal antibodies which characterize 
neurological paraneoplastic disorders. This contrasts antibodies to voltage-gated potassium or 
calcium channels located at nerve terminals, which may lead to limbic encephalitis and 
paraneoplastic cerebellar degeneration respectively (for review see (Dropcho, 2005)). Limbic 
encephalitis may also be associated with antibodies to NMDA receptors (Graus et al., 2008). 
In a recent study on 38 patients with antibodies to the onconeuronal protein Ma-2, five 
patients were indentified with excessive daytime sleepiness, and low to undetectable 
hypocretin in the CSF that may indicate hypothalamic dysfunction (Dalmau et al., 2004). 
However, anti-Ma-2 autoantibodies were not detected in patients with narcolepsy (n=19), the 
mean duration of illness being 9.7  8.3 years (Overeem et al., 2004). However, the clinical 
spectrum of anti-neuronal antibodies may be much broader. For example, the risk of 
Parkinson disease is increased among women with autoimmune diseases including Graves’ 
disease, insulin-dependent diabetes and pernicious anaemia (Rugbjerg et al., 2009). These 
data may indicate the presence of autoantibodies to dopaminergic neurons.  
 
Are there signs of inflammation in the central nervous system in narcolepsy? 
In autoimmune diseases, histological examinations frequently reveal cellular infiltrates 
consisting of lymphocytes, plasma cells and macrophages in areas of tissue destruction. It is 
therefore of importance to determine whether this is seen in narcolepsy. What regions in the 
CNS should be analyzed in depth? As outlined above, special attention should be given to 
hypocretin-1 and hypocretin-2 producing neurons in the hypothalamus, and to the hypocretin 
projection fields. Since the disease does not reduce life expectancy, histological examination 
of brains is hardly an available option. In one patient having a hypocretin mutation, early 
onset narcolepsy (age 6 months) and a long follow up over many years, histological analysis 
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did not show ‘obvious lesions’ and the presence of a mild astrogliosis in the perifornical area 
remains controversial (Honda et al., 2009, Thannickal et al., 2009). Most importantly, 
immunohistochemical staining of HLA-DR revealed normally distributed resting microglia in 
both the white and grey matter of two narcoleptic subjects. Neither of the cases (aged 77 yr 
and 67 yr) was associated with activated, amoeboid microglia. This is remarkable, since the 
upregulation of HLA-DR expression and microglia activation are hallmarks of immune 
mediated inflammation in the CNS. In the context of a description of dysregulated TNF 
expression (see below) it is interesting to note that in-situ hybridization for TNF RNA did not 
reveal a significant signal in control and narcoleptic tissue (Peyron et al., 2000). Taken 
together, these findings do not support the model that T cells and macrophages induce a 
reduction in the numbers of hypocretin neurons. However, altered MHCI, MHCII and TNF 
expression may only be seen early on, at the time of the loss of hypocretin neurons, but not 
years after onset of disease. 
 
Are tumour necrosis factor  and its receptors critical for the pathogenesis of 
narcolepsy? 
A growing body of evidence supports a role of the cytokine tumour necrosis factor- (TNF) 
in sleep disorders, including narcolepsy, fatigue in infectious and autoimmune diseases and in 
sleep apnoea. TNF is a homotrimeric cytokine that binds to two receptors, TNFRI and 
TNFRII. TNF is synthesized as a type-2 transmembrane protein that is inserted into the 
membrane as a homotrimer and cleaved by the matrix metalloprotease TNF alpha converting 
enzyme (TACE, ADAM 17) to a 51 kDa soluble circulating trimer (Idriss and Naismith, 
2000). Both membrane-bound and soluble forms are mainly produced by monocytes, 
macrophages and dendritic cells. In the context of sleep disorders, it is of note that TNF is 
produced in the CNS, mainly by microglia cells and astrocytes, but also by neurons (Frei et 
al., 1989, Lieberman et al., 1989, Probert and Akassoglou, 2001). TNF binds to TNF receptor 
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1 (TNFRI) and TNF receptor 2 (TNFRII), which are membrane glycoprotein receptors. 
TNFRI is expressed on all types of cells and binds membrane-bound TNF (mTNF) as well as 
soluble TNF (sTNF). This contrasts with TNFRII, which is mainly expressed on cells of the 
immune system, including microglia, and by endothelial cells, and which binds only mTNF 
(Wajant et al., 2003). TNF is a pleiotropic inflammatory cytokine that acts on parenchymal 
cells in various organs, including the CNS, in which it modulates the functions of microglia, 
oligodendrocytes, astrocytes and neurons. With respect to sleep disorders it is of note that 
TNF alters glutaminergic transmission and synaptic plasticity and scaling. TNF increases 
AMPA receptors on neurons and leads to inhibition of the expression of GABAA receptors 
which together leads to increased excitatory synaptic transmission (Beattie et al., 2002, 
Campbell and Trowsdale, 1993, Stellwagen et al., 2005, Stellwagen and Malenka, 2006). The 
TNF locus is situated within the Class III region of the human MHC complex on chromosome 
6p21. In light of the association of narcolepsy with HLA-DQB1*0602 it is interesting to study 
the expression of this cytokine in narcoleptic patients.  
 
Interleukin (IL)-1, IL-1 receptor antagonist, IL-2, TNF and lymphotoxin-alpha in plasma 
and in mitogen-stimulated monocytes and lymphocytes were not found to differ between 
narcolepsy patients and HLA-DR2 matched control subjects (Hinze-Selch et al., 1998). Only 
IL-6 was found to be increased in lipopolysaccharide activated monocytes in narcolepsy. 
However, increased TNF and IL-6 serum levels compared to age and gender matched controls 
were detected in a later study by Okun, et al., who found the TNF concentration in patient’s 
sera to be 13.9  1.39 pg/ml (control: 8.2  0.45 pg/ml) and the IL-6 concentrations to be 6.7 
1.45 pg/ml (control: 0.49  0.09 pg/ml for IL-6) (Okun et al., 2004). In the latter study, 
stimulatory drugs were associated with lower TNF levels. As outlined above, genetic 
polymorphism in the Tnf promoter may also influence TNF serum concentrations. The TNF 
allele with the C-857T polymorphism was strongly associated in the subgroup of 
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DRB1*15/16 (HLA-DR2 type) negative patients (Wieczorek et al., 2003). In a recent well 
controlled study, new information was obtained by Himmerich et al. (Himmerich et al., 
2006). Whereas serum TNF was not increased, narcoleptic patients had higher soluble (s) 
TNFRII (but not sTNFRI) compared to controls. This may be explained by genetic 
polymorphisms. Positive correlations have been observed for the TNF (-857T) and TNFRII (-
196T) combination with narcolepsy, and for DRB1*1501 and TNF (-857T) (Hohjoh et al., 
2001, Hohjoh et al., 2001). Further studies should address the relationship between sTNFRII 
and HLA-DR2.  
Collectively, there is evidence that TNF and sTNFR serum concentrations are abnormal in 
patients with narcolepsy and that there are Tnf and TNFRII gene polymorphisms that are 
linked to the HLA-DQB1*0602 allele. It is of note, however, that the TNF promoter -857T 
allele, which correlated with the presence of the TNFRII -196T allele in narcolepsy, has been 
found to be associated with an almost twice as high TNF produced by blood mononuclear 
cells (Hohjoh and Tokunaga, 2001). Elevated plasma levels of sTNFRII have not only been 
detected in narcolepsy, but also in inflammatory diseases including rheumatoid arthritis 
(Glossop et al., 2005). The extent of production of mTNF, sTNF and TNFR in the 
hypothalamus at onset of disease has not yet been explored. It is open whether production of 
TNF and TNFRII follows activation of MHCII expressing cells and neurons, or follows tissue 
injury (Knoblach et al., 1999). 
 
The studies on narcolepsy outlined above are also intriguing because subcutaneous infusion of 
TNF impairs locomotor activity in mice and lowers the expression of clock genes in the liver. 
TNF acts on clock genes that are regulated by E-boxes in their promoters - namely the PAR 
bZip clock controlled genes Dbp, Tef and Hlf and the period genes Per1, Per2 and Per3 - but 
not Clock nor Bmal1, which lack E-boxes in their regulatory DNA regions (Cavadini et al., 
2007). Since clock genes are central in the sleep-wake cycle and map to mouse chromosome 5 
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within a region syntenic to human chromosome 4g12, a region close to the narcolepsy 
susceptibility locus 4p/3-q21 identified recently, polymorphisms have been analysed in the 
Clock gene (Nakayama et al., 2000). However, no differences in allelic and genotypic 
frequencies of two clock polymorphisms have been observed in narcolepsy compared to 
controls (Moreira et al., 2005). 
 
Death of hypocretin expressing neurons in narcolepsy from an immunological point of 
view 
Taking into account the immunological features of narcolepsy outlined above (HLA-
DQB1*0602 association, polymorphisms in the TNF/TNFR genes and in the T cell receptor 
alpha (TCR [alpha]) locus, anti–Trib2 antibodies), death of hypocretin neurons in 
narcolepsy could be immune mediated. T cell cytotoxicity mediated by MHCI restricted 
neuronal killing is unlikely. Antigen-specific lysis of target cells by cytotoxic CD8+ T cells 
requires expression of MHCI antigens (Walter and Santamaria, 2005). However in the normal 
CNS, these molecules are not expressed, or only at low levels, in synapses and dendrites of 
neurons (Goddard et al., 2007). The induction of MHCI molecules and 2-microglobulin also 
depends on membrane depolarization (Neumann et al., 1995, Rensing-Ehl et al., 1996). In 
autoimmune and viral diseases of the CNS there is still no convincing evidence for MHCI-
dependent killing of neurons by CD8+ T cells. The sensitivity of neurons to cytotoxic CD8+ T 
cell-mediated killing has only been demonstrated convincingly with neurons transfected with 
a gene encoding an MHC class I (MHCI) molecule (Joly et al., 1991, Rall et al., 1995). 
 
MHCII molecules such as HLA-DR2 and HLA-DQB1*0602 bind (self) antigens and interact 
with antigen-specific TCRs on CD4+ T cells (Chen et al., 2009). MHCII in the CNS is only 
expressed by microglia and by blood derived monocytes, perivascular macrophages and 
dendritic cells. These cells may activate invading CD4+ T cells in an antigen and MHCII 
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dependent manner. However, autoptic studies in narcolepsy have detected neither T cells nor 
increased MHCII expression in the hypothalamus. Since these studies were performed with 
tissues from patients with long lasting disease, it cannot be excluded that the picture might be 
very different at the onset of narcolepsy. CD4+ T cells may recognise bacterial antigens, e.g. 
streptococcal antigens, and/or self antigens. The latter could be a consequence of molecular 
mimicry between host and pathogen as shown for example in post-streptococcal Sydenham 
chorea (Kirvan et al., 2003). Patients with narcolepsy (n= 200) that are characterized by being 
DQB1*0602 positive and low hypocretin in the CSF have recently been found to have 
increased antibodies to streptolysin (ASO) and to DNAseB (ADB) within the first three years 
after onset of disease when compared to age-matched controls (n= 200) (Aran et al., 2009). C-
reactive protein levels were not increased. ASO and ADB titers were highest close to 
narcolepsy onset, and decreased with disease duration. This contrasts with anti-Helicobacter 
pylori antibodies, which did not differ from controls. Clinical studies showed that the risk of 
narcolepsy in a person with a history of a physician-diagnosed streptococcal throat infection 
before age 21 was 5.4-fold higher than in individuals without such a history (Longstreth et al., 
2009). Twenty years ago, increased ASO and ADB titers were observed in a small number of 
narcoleptic patients, although this finding was not reproduced later (Billiard et al., 1989, 
Mueller-Eckhardt et al., 1990). Group size and the time interval between onset of disease and 
blood testing may contribute to differences in the data.  
 
Immune-mediated bystander killing of neurons 
In narcolepsy, the loss of neurons is very selective and includes neurons expressing 
hypocretin-1, but not neighbouring neurons which produce melanin-concentrating hormone 
(MCH) (Blouin et al., 2005, Thannickal et al., 2009). Selectivity could be due to neurotoxic 
autoantibodies binding to unique antigens expressed only by hypocretin neurons. However, 
such antibodies have not been detected so far (see above).  
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Because neurons express only low levels of MHCI/II, T lymphocytes are unlikely to interact 
in an antigen-dependent way with neuronal cells. However, T cell mediated killing of neurons 
could be indirect, neurotoxicity being due to T cell mediated bystander killing. For example 
CA1 hippocampal neurons expressing a transgene encoding the nucleoprotein (NP) of Borna 
disease virus (BDV) showed no damage when mice were injected with BDV-specific CD8+ T 
cells (Richter et al., 2009). This contrasts with mice expressing the NP of BDV in astrocytes. 
In this situation, BDV-specific CD8+ T cells were found to interact with regional NP positive 
astrocytes and thereby caused collateral damage to uninfected CA1 neurons. This effect was 
thought to be the result of neurotoxic molecules released from functionally impaired 
astrocytes (Richter et al., 2009). Using glutamate receptor antagonists, death of uninfected 
hippocampal CA1 neurons due to glutamate receptor overstimulation was excluded. The 
authors suggest that the interaction of CD8+ T cells with astrocytes may impair astrocyte 
mediated detoxification of potentially neurotoxic molecules or the production of neurotrophic 
factors by astrocytes (Richter et al., 2009). Likewise, anti-self CD8+ T cells may cause 
bystander toxicity by acting on astrocytes expressing MHCI, the cellular interaction causing 
death of hypocretin neurons. Bystander neurotoxicity has also been observed to develop in the 
course of the generation of cytotoxic CD8+ T cells that recognize virus (e.g. JC virus) infected 
MHCI positive oligodendrocytes (for review see (Melzer et al., 2009)). Another example of 
bystander neurotoxicity is provided by studies using ovalbumin-specific CD4+ T cells. These 
cells lead to a lethal MHCII- and antigen-independent increase in neuronal calcium, which 
could be prevented by blocking glutamate receptors and perforin (Nitsch et al., 2004). 
 
Neurotoxicity by CD4+ T cells may either be mediated by their release of neurotoxic 
molecules, including interferon gamma (IFN), TNF or lymphotoxin  or be due to their 
ability to activate microglia to produce the aforementioned cytokines, as well as radical 
oxygen intermediates (ROI), nitric oxide (NO) and glutamate (figure) (Piani et al., 1992). 
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TNF by itself is capable of inducing largely unselective, high-conductance ion channels 
following ph - dependent insertion into lipid bilayer or cell membranes (Baldwin et al., 1996, 
Kagan et al., 1992). It is interesting that in rat hypothalamic slice cultures the addition of N-
methyl-D-aspartate resulted in a marked decrease in the number of hypocretin neurons, 
whereas neurons expressing MCH were relatively spared (Katsuki and Akaike, 2004). 
Quinolinic acid, a tryptophan metabolite produced by the kynurenine pathway, posesses an 
agonist activity on NMDA receptors and leads to selective loss of hypocretin neurons. 
Microglia cells and blood derived moncytes/macrophages are prominent sources of quinolinic 
acid (Stone, 2001). Hypocretin neurons express NMDA receptors, the glutaminergic inputs 
regulating their electrical activity (Li et al., 2002). In contrast to neurons expressing MCH, 
hypocretin neurons are inhibited by elevation of extracellular glucose, the effect being 
mediated by subunits of the TASK subfamily of two pore potassium (K2P) channels 
(Burdakov et al., 2006). Differences of MCH neurons and hypocretin neurons, which may 
result in selective killing of hypocretin neurons, may also depend on ectopic expression of 
death receptors including TNFR or Fas or a high degree of sensitivity towards proapoptotic 
signals. The latter may be due to the absence of anti-apoptotic intracellular molecules or of 
neuroprotective factors or their receptors. Regulation of apoptosis is central in the 
neuroprotection and neurodegeneration (Okouchi et al., 2007). 
To assess T cell autoimmunity in narcolepsy, further work should examine (1) whether there 
is a restricted usage of T cell receptor genes in the CSF, (2) whether T cell activation and 
neurotoxic effects of T cells from patients are observed in co-cultures with immortalized 
hypothalamic neurons transfected with HLA-DR2 genes, (3) whether signs of narcolepsy 
develop in humanized severe combined immunodeficiency mice that express human HLA-
DR2 genes and are injected with reactivated CD4+ T cells from narcoleptic patients and, (4) 
whether monoclonal antibodies with streptococcal reactivity can induce apoptosis of 
hypocretin neurons in-vitro. 
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Superantigen induced T cell activation and neurotoxicity 
An alternative model is that infectious pathogens in the hypothalamus may express 
superantigens that bridge the TCR on T cells with MHCII molecules expressed by cells such 
as microglia. Bacterial or viral superantigens concentrate on the surface of antigen presenting 
cells by binding to MHCII molecules and then engage and crosslink multiple TCR molecules, 
resulting in strong TCR signalling, T cell activation and cytokine production. IFN-released 
by superantigen activated T cells may lead to neuronal excitotoxicity by intracellular trans-
signalling between the IFN- receptor and a Ca2+- permeable neuronal AMPA/kainate 
receptor in the absence of extracellular glutamate (Mizuno et al., 2008). As a hypothesis, the 
narcolepsy associated polymorphism of the TCR locus, as well as DQB1*0602 on cells such 
as microglia, might permit only a limited engagement of the TCR in the superantigen-
dependent process, and thereby cause only minimal inflammation (figure). A stronger 
interaction would be inconsistent with the limited pathology and destruction of only one type 
of cell – the hypocretin neurons in the hypothalamus. Most superantigens interact with TCR 
molecules by binding primarily to the variable region of the  chain (for review: (Fraser and 
Proft, 2008)). It might thus seem unlikely that the recently observed polymorphism in the 
TCR locus could reflect the involvement of superantigens in narcolepsy. However, there are 
also superantigens that bind to alpha chains of the TCR. The staphylococcal toxin SHE 
recognises the variable region of the TCR-chain (V27) (Pumphrey et al., 2007) and the 
mycoplasma arthritidis mitogen consists of two -helical bundles, one of which binds 
orthogonally to the top of the MHCII1-helix, peptide and 1-helix (Zhao et al., 2004).  
 
T cell independent MHCII mediated neurotoxicity 
In T cell mediated diseases of the CNS, such as multiple sclerosis or experimental 
autoimmune encephalomyelitis, the function of MHCII is primarily that of antigen 
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presentation by microglia and macrophages. However, in conditions such as Huntington’s 
disease and Parkinson’s disease, or brain trauma, the aforementioned types of cells express 
MHCII despite the fact that no evidence for T cell involvement has been observed. In these 
diseases, upregulation of MHCII in microglia cells may follow the ingestion of apoptotic cells 
(Hellendall and Ting, 1997). Necrotic neurons have been shown to activate microglia to 
upregulate MHCII, costimulatory molecules (CD40), CD24, 2 integrin, CD11b, inducible 
nitric oxide synthetase, and cytokines including TNF (Pais et al., 2008). It has been suggested 
that an alternative role for MHCII might involve signal transduction leading to activation, 
differentiation and production of proinflammatory cytokines. Cuprizone-induced 
oligodendrocyte dysfunction with T cell independent demyelination pathology is much less 
pronounced in MHCII I-A (beta)-/- mice, or in mice expressing a truncated I-A (beta) chain 
lacking a cytoplasmic domain. It is not clear yet how signalling by MHCII molecules is 
activated in the absence of T cell function (Hiremath et al., 2008, Matsushima et al., 1994). 
These findings may be of relevance for narcolepsy. As a hypothesis, infectious pathogens 
may have a tropism for hypothalamic hypocretin neurons and thereby cause these neurons to 
activate microglia to increase signalling via their MHCII molecules (figure). Activated 
microglia induce neurotoxicity by releasing quinolinic acid or through the upregulation of 
glutaminase, an enzyme that produces the NMDA receptor agonist glutamate (Pais et al., 
2008, Piani et al., 1991, Piani et al., 1992). The activation of microglia by necrotic neurons 
was shown to be dependent on the TLR- associated adaptor molecule myeloid differentiation 
primary response gene (MyD88).  
 
Conclusion 
Autoimmunity, superantigen mediated T cell activation and non T cell mediated activation by 
MHCII signalling – could be involved in narcolepsy. Whereas HLA-DQB1*0602 might select 
for recognition of selfantigens and thereby lead to autoimmunity, the polymorphism of the 
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TCR (alpha) gene might be crucial in superantigen mediated T cell activation. The existence 
of CD8+ mediated neuronal cell death has not yet been convincingly proven in-vivo. However, 
CD8+ induced damage of MHCI expressing astrocytes or oligodendrocytes may be followed 
by collateral toxicity to neurons. HLA-DQB1*0602 might be more vulnerable to T cell 
independent, MHCII mediated activation of macrophages and microglia. These cells have 
been shown to release neurotoxic molecules including Fas ligand, proteases, TNF, quinolinic 
acid, glutamate, ROI and NO. Selectivity of killing of hypocretin neurons may be due to a 
high degree of sensitivity towards the aforementioned cytotoxic molecules as has been shown 
with quinolinic acid. The detection of an increased frequency of streptococcal infection in 
narcolepsy may provide a hint for molecular mimicry and autoimmunity or for the 
involvement of superantigens as initiators of T cell activation. For the detection of anti-CNS 
antibodies and activation of T cells / monocytes in the blood, future studies should 
concentrate on patients with a newly diagnosed or very recent onset of disease.  
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Table 1  Autoimmunity in Narcolepsy? 
Pro  
 
- Association with HLA-DR2/DQB1*0602 
- Polymorphism in the T cell receptor  
(alpha) locus 
- Dysregulation of TNF/TNF receptor system 
- Increased antibodies to streptolysin and to 
DNAseB 
- Anti–Trib2 antibodies  
 
Langdon and Curnow, 1984; Matsuki et al., 2009 
Hallmayer et al., 2009 
 
Okun et al., 2004; Himmerich et al., 2006; Hohjoh et al., 2001 
Aran et al., 2009; Billiard et al., 1989 
 
Cvetkovic-Lopes et al., 2010 
Contra  
- Only rare association with known 
autoimmune diseases in patients with 
narcolepsy, or in their families (e.g. SLE, 
multiple sclerosis) 
- No autoantibodies to nuclear proteins 
(antinuclear antibodies, anti-nDNA) 
- Usually no increase in IgG index and no 
oligoclonal bands in CSF 
- No narcolepsy specific antibodies (anti-
neuronal, anti- hypocretin , anti-hypocretin 
receptor) 
- No signs of inflammation in autopsy studies 
and no elevation of CRP 
- No TNF gene expression in the CNS 
 
Pablos et al., 1993 ; Torn Baba et al., 2009 
 
 
 
Rubin et al., 1988 
 
Fredrickson et al., 1990 ; Schuld, 2004 
 
Black et al., 2005 ; Tanaka et al., 2006 
 
 
Thannickal et al., 2009; Honda et al., 2009; Aran et al., 2009 
 
Peyron et al., 2000 
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Figure legend 
Autoantibody, T-lymphocyte and microglia induced killing of hypocretin neurons 
(1) Hypocretin neurons may be destroyed by autoantibodies such as Trib2 (Cvetkovic-Lopes 
et al., 2010) which are produced by B cells. 
 
(2) Priming of CD4+ T cells to selfantigens presented to T cell receptor (TCR) by 
DQB1*0602 expressing antigen presenting cells (APC) including dendritic cells, monocytes, 
macrophages and microglia cells leads to activation of B cells and of APC. The latter produce 
neurotoxic factors such as quinolinic acid, glutamate, radical oxygen intermediates (ROI) and 
tumour necrosis factor alpha (TNF) (Katsuki and Akaike, 2004).  
 
(3) Since the significance of the expression of MHCI molecules on neurons in-vivo is still a 
matter of debate the contribution of CD8+ T cell mediated killing of neurons remains open. 
However there is evidence for CD8+ T cell mediated antigen dependent interaction with 
MHCI expressing astrocytes (A) or oligodendrocytes (O) which as reported may result in 
damage of these glial cells and collateral toxicity of neurons (Melzer et al., 2009, Richter et 
al., 2009). 
 
(4) Neurotoxic molecules may also be released by APC that bind bacterial or viral 
superantigens via MHCII molecules. Crosslinking of T cell receptors on T cells leads to 
release of neurotoxic molecules including interferon gamma (IFN-and TNF.  
 
(5) Activation of microglia cells or other antigen presenting cells (APC) including dendritic 
cells and monocyte derived macrophages may also be mediated by signalling through MHCII 
molecules in the absence of T cells (Hiremath et al., 2008, Matsushima et al., 1994). The 
 41
ligand, which bind to MHCII as well as the origin of the ligand (hypocretin neurons?), are not 
known. MHCII mediated activation of APC leads to the release of neurotoxic molecules. 
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